Prostatic neoplasms, castration-resistant
Clinical trials for Prostatic neoplasms, castration-resistant explained in plain language.
Never miss a new study
Get alerted when new Prostatic neoplasms, castration-resistant trials appear
Sign up with your email to follow new studies for Prostatic neoplasms, castration-resistant, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Cancer drug safety tracked in ongoing rollover trial
Disease control By invitation onlyThis study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New cocktail of drugs shows promise for Hard-to-Treat prostate cancer
Disease control OngoingThis phase 2 trial is testing several drug combinations—including niraparib, cetrelimab, abiraterone acetate, and prednisone—in 136 men with metastatic castration-resistant prostate cancer (mCRPC), a form of the disease that has spread and stopped responding to standard hormone t…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New radioactive therapy aims to control advanced prostate cancer
Disease control OngoingThis early-stage study tests a radioactive drug called 225Ac-PSMA-617 in men with PSMA-positive prostate cancer that has stopped responding to hormone therapy. The goal is to find a safe dose and see if it can help control the cancer, even in men who have already received a simil…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase 1 • Sponsor: Endocyte • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Prostate cancer drug interaction study aims to improve safety
Knowledge-focused OngoingThis study looks at how the experimental drug JNJ-56021927 changes the way the body processes several common medications in men with castration-resistant prostate cancer. About 23 participants will receive the cancer drug along with a cocktail of other drugs to measure how their …
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase 1 • Sponsor: Aragon Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC